Drug Discovery World

JULY 3, 2023

DDW’s Diana Spencer speaks to the CEOs of two drug discovery start-ups to find out how they have overcome the challenges of launching a new company in a competitive market. It’s a challenging time to launch a new company in the life sciences sector. It’s not easy being the new kid on the block.

Life Science 52

Life Science Pharma Companies Drugs Marketing 52

Drug Discovery World

APRIL 27, 2023

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. We believed that having a fully human CD3 antibody may offer benefits to patients across many different chronic disease indications.”

Antibody 52

Antibody Development Life Science FDA Approval 52

XTalks

JANUARY 5, 2021

Both drug discovery and drug repurposing to manage and treat the disease will also continue as experts learn more about the virology and epidemiology of the novel SARS-CoV-2 coronavirus that wreaked havoc in 2020. These include monoclonal antibody drugs, which are attractive therapeutic agents owing to their targeted specificity.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

Pharmaceutical Technology

APRIL 14, 2023

TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients. The first-in-class, clinical-stage antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN 6), TORL-1-23 is being developed to treat patients across several cancer types. CLDN 18.2).

Development 264

Development Clinical Trials Clinical Trials Life Science 264

XTalks

AUGUST 18, 2021

In this episode, Ayesha discussed the US Food and Drug Administration’s (FDA) authorization of a third dose of the Pfizer and Moderna COVID-19 vaccines for immunocompromised individuals. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Vaccination Vaccine Antibody 52

BioSpace

APRIL 3, 2024

Amid a flurry of deals in the antibody-drug conjugate space, Merck KGaA is getting in on the action with a partnership with Caris Life Sciences to accelerate the discovery and development of first-in-class ADCs for oncology.

Life Science 58

Life Science Development Antibody Drugs 58

XTalks

JULY 25, 2022

Byondis announced that the US Food and Drug Administration (FDA) accepted their Biologics License Application (BLA) for [vic-]trastuzumab duocarmazine (SYD985), an investigational therapy being studied to treat HER2-positive unresectable locally advanced or metastatic breast cancer. Treating HER2-Positive Metastatic Breast Cancer.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

The Pharma Data

MARCH 15, 2022

For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections , Inc. Global Head of Blackstone Life Sciences “We are excited to collaborate with Sanofi’s experienced development team to advance a subcutaneous dosage form for Sarclisa for patients.

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

BioTech 365

OCTOBER 12, 2021

NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc.

Antibody 52

Antibody Development Life Science Drugs 52

BioSpace

MARCH 14, 2021

Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.

Life Science 94

Life Science Antibody Licensing Licensing 94

XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Life Science 98

Life Science Vaccination Vaccine Trials 98

XTalks

FEBRUARY 29, 2024

Two years after its approval in 2021 , Biogen has decided to pull the plug on its Alzheimer’s drug Aduhelm (aducanumab). In a statement , the company said it will discontinue Aduhelm to focus efforts on its other amyloid beta-directed antibody Leqembi (lecanemab) for Alzheimer’s and focus on developing other new treatments.

Drugs 59

Drugs FDA Approval Antibody Life Science 59

Drug Discovery World

JULY 18, 2022

Life sciences company Carterra has joined data cloud company TetraScience’s network of partners to help generate insights into the potential of antibodies as drug candidates. . The Tetra Partner Network (TPN) is an ecosystem of partners which connects R&D data for pharmaceutical and biopharmaceutical customers. .

Antibody 52

Antibody Life Science Drugs Development 52

XTalks

SEPTEMBER 7, 2021

After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, new data shows that while those variants may be resistant to the drugs, the currently dominating Delta variant may not be. 1 and Beta/B.1.351,

Antibody 97

Antibody In-Vitro Drugs Sales 97

Drug Discovery World

JANUARY 10, 2023

For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. Antibody validation. Antibody validation. A proposal for validation of antibodies.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

MARCH 21, 2024

This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Flow cytometry technologies and cancer associated fibroblasts and Leveraging flow cytometry in drug discovery.

Research 52

Research Drugs Life Science Scientist 52

Drug Discovery World

DECEMBER 14, 2023

With leading academic institutions and significant recent investment, Glasgow is shaping up to be an important centre for drug discovery and development in the UK. A centre of excellence for cancer research The announcement of the new Health Innovation Hub follows other examples of significant investment in Glasgow life sciences.

Drugs 75

Drugs Life Science Research Scientist 75

pharmaphorum

JANUARY 12, 2024

Discover the top six key takeaways from JP Morgan's 2024 conference, focusing on dealmaking trends in big tech, life science, AI, and advancements in cell and gene therapies, as well as the future of Antibody-drug conjugates (ADCs). Stay informed with the latest industry insights.

Gene Therapy 59

Gene Therapy Life Science Antibody Gene 59

Drug Discovery World

FEBRUARY 19, 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Development 59

Development Gene Therapy Drugs Antibody 59

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong. expressing cancers.

Development 64

Development Research Drugs Antibody 64

Drug Discovery World

MARCH 31, 2023

As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.

Drugs 52

Drugs Antibody Vaccination Vaccine 52

XTalks

OCTOBER 27, 2022

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US Food and Drug Administration (FDA) approved Tecvayli (teclistamab-cqyv) for the treatment of relapsed or refractory multiple myeloma. Tecvayli is a first-in-class, bispecific T-cell engager antibody administered as a subcutaneous treatment.

FDA Approval 52

FDA Approval Antibody Drugs Trials 52

XTalks

NOVEMBER 3, 2021

The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). The implant is surgically placed in the eye and injected with Genentech’s anti-VEGFA monoclonal antibody ranibizumab for continuous delivery.

Life Science 52

Life Science Drug Delivery Systems Vaccination Vaccine 52

Drug Discovery World

SEPTEMBER 8, 2023

Intelligent OMICS and Janssen enter AI research collaboration AI drug discovery company Intelligent OMICS and Janssen Research & Development have agreed a target discovery collaboration to evaluate novel biological targets for the treatment of haematological cancers.

Drugs 52

Drugs Life Science Antibody Licensing 52

pharmaphorum

JULY 19, 2021

A complex medicine applies novel technologies that deliver or target drugs, by modification of a pharmaceutical ingredient, formulation or using a new delivery route. Through partnership and innovation in solving the technical challenges, the development of new complex drug classes can rapidly address challenging medical needs.

Life Science 52

Life Science Medicine RNA Vaccination 52

XTalks

JULY 28, 2021

Ayesha and the team talked about the controversial approval of the drug, with lingering questions about its clinical benefit despite having the ability to reduce amyloid plaques as an anti-amyloid monoclonal antibody. The team also talked about Pfizer’s expanded recall of its smoking cessation drug Chantix, which now involves 12 lots.

Life Science 52

Life Science FDA Approval Drugs Antibody 52

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. We aim to continue to ‘open up’ the druggable antibody space.”

Drugs 52

Drugs Antibody DNA Gene Therapy 52

BioPharma Reporter

MAY 24, 2023

Purolite, an Ecolab company based in Pennsylvania, is a leading manufacturer of healthcare, pharmaceutical and life science products. The company is concerned with projects involving purification of mRNA vaccines and monoclonal antibodies for cancer-treatment drugs, among others.

Life Science 52

Life Science Antibody Manufacturing Vaccination 52

XTalks

AUGUST 18, 2023

After Johnson & Johnson’s US Food and Drug Administration (FDA) approval last week for its second multiple myeloma bispecific, Talvey (talquetamab), Pfizer received an FDA nod for its B-cell maturation antigen (BCMA)-directed therapy Elrexfio (elranatamab) in the same indication. Elrexfio is Pfizer’s first approved multiple myeloma drug.

FDA Approval 98

FDA Approval Drugs Antibody Trials 98

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19. Regeneron Pharmaceuticals Inc.’s

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

pharmaphorum

MAY 20, 2021

Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.

Antibody 52

Antibody Development Clinical Development Life Science 52

Pharmaceutical Technology

APRIL 18, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Glycoside hydrolase-based drug compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Drugs 130

Drugs Antibody Life Science DNA 130

Drug Discovery World

MAY 25, 2023

Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. The post The latest drug discovery product launches appeared first on Drug Discovery World (DDW). DDW provides an update.

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

APRIL 28, 2023

Each of our top five stories this week exemplify the scientific curiosity that fuels the drug discovery sector, ultimately leading to better treatments for patients. The stories cover the efforts by research teams to discover innovative novel drugs for geographic atrophy, HIV, lung cancer, anxiety and diabetes.

Drugs 52

Drugs Life Science Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The 2024 Drugs to Watch, are: 1. Due to a delayed US launch it remains a drug to watch for 2024.

Drugs 69

Drugs Antibody Gene Editing Medicine 69

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: How are aptamers currently used in the development of precision treatments?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52